UNLOXCYT (COSIBELIMAB)
UNLOXCYT (COSIBELIMAB) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: UNLOXCYT; Generic name: COSIBELIMAB; Drug class: Programmed Death Ligand-1 Blocker [EPC].
| Brand name | UNLOXCYT |
|---|---|
| Generic name | COSIBELIMAB |
| Drug class | Programmed Death Ligand-1 Blocker [EPC] |
| Manufacturer | Sun Pharmaceutical Industries, Inc. |
| Used for | 1. INDICATIONS AND USAGE UNLOXCYT is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. UNLOXCYT is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. |
| Dosage | 2. DOSAGE AND ADMINISTRATION The recommended dosage of UNLOXCYT is 1,200 mg as an intravenous infusion over 60 minutes every 3 weeks. ( 2.1 ) 2.1. Recommended Dosage The recommended dosage of UNLOXCYT is 1,200 mg administered as an intravenous infusion over 60 minutes every 3 weeks until disease progression or unacceptable toxicity. 2.2. Dose Modifications for Adverse Reactions No dose reductions of UNLOXCYT are recommended. In general, withhold UNLOXCYT for severe (Grade 3) immune-mediated adve |
| Active ingredient(s) | COSIBELIMAB |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06bdadd5-d2db-406f-a3f8-de47f48a52e3 |